CliffordAHudisMD

PubMed

• 178 citations
  Celecoxib, a selective cyclooxygenase 2 inhibitor, protects against human epidermal growth factor receptor 2 (HER-2)/neu-induced breast cancer.
  Louise R. Howe, Kotha Subbaramaiah, Jay P. Patel, Jaime L. Masferrer, Aparna Deora
  Cancer Research. 2002-10-01
• 837 citations
  ESR1 ligand-binding domain mutations in hormone-resistant breast cancer
  Weiyi Toy, Yang Shen, Helen Won, Bradley Green, Rita A. Sakr
  Nature Genetics. 2013-12-01
• 51 citations
  Sorafenib or Placebo with Either Gemcitabine or Capecitabine in Patients with HER-2–Negative Advanced Breast Cancer That Progressed during or after Bevacizumab
  Lee S. Schwartzberg, Kurt W. Tauer, Robert Hermann, Grace Makari-Judson, Claudine Isaacs
  Clinical Cancer Research. 2013-05-15

Journal Articles

• Science and Society: Fifty Years Later-The 2014 Presidential Address  
  Hudis C, J Clin Oncol, 1/10/2015
• A phase II open-label study of ganetespib, a novel heat shock protein 90 inhibitor for patients with metastatic breast cancer  
  Jhaveri K, Chandarlapaty S, Lake D, Gilewski T, Robson M, Goldfarb S, Drulinsky P, Sugarman S, Leiblich CW, Fasano J, Moynahan ME, D'Andrea G, Lim K, Reddington L, Haq..., Clin Breast Cancer, 1/1/2014
• Associations among survivorship care plans, experiences of survivorship care, and functioning in older breast cancer survivors: CALGB/Alliance 369901  
  Faul LA, Luta G, Sheppard V, Isaacs C, Cohen HJ, Muss HB, Yung R, Clapp JD, Winer E, Hudis C, Tallarico M, Wang J, Barry WT, Mandelblatt JS, J Cancer Surviv, 1/1/2014
• Building a rapid learning health care system for oncology: the regulatory framework of Cancer LinQ  
  Schilsky RL, Michels DL, Kearbey AH, Yu PP, Hudis CA, J Clin Oncol, 1/1/2014
• Adjuvant endocrine therapy for women with hormone receptor-positive breast cancer: American society of clinical oncology clinical practice guideline focused update  
  Burstein HJ, Temin S, Anderson H, Bucholz TA, Davidson NE, Gelmon KE, Giordano SH, Hudis CA, Rowden D, Solky AJ, Stearns V, Winer EP, Griggs JJ, J Clin Oncol, 1/1/2014
• Impact of the addition of carboplatin and/or bevacizumab to neoadjuvant once-per-week paclitaxel followed by dose-dense doxorubicin and cyclophosphamide on pathologic ...  
  Sikov Wm, Berry DA, Perou CM, Singh B, Cirrincione CT, Tolaney SM, Kuzma CS, Pluard TJ, Somlo G, Port ER, Golshan M, Bellon JR, Collyar D, Hahn OM, Carey LA, Hudis CA,..., J Clin Oncol, 1/1/2014
• American Society of Clinical Oncology Position Statement on Obesity and Cancer  
  Ligibel JA, Alfano CM, Couneya KS, Demark-Wahnefried W, Burger RA, Chlebowski RT, Fabian CJ, Gucalp A, Hershman DL , Hudson MM, Jones LW, Kakarala M, Ness KK, Merrill ..., J Clin Oncol, 1/1/2014
• Web based pathology assessment in RTOG 98-04  
  Woodward WA, Sneige N, Winter K, Kuerer HM, Hudis C, Rakovitch E, Smith BL, Pierce LJ, Germano I, Pu AT, Walker EM, Grisell DL, White JR, McCormick B for the Radiatio..., J Clin Pathology, 1/1/2014
• Comparison of doxorubicin and cyclophosphamide versus single-agent paclitaxel as adjuvant therapy for breast cancer in women with 0 to 3 positive axillary nodes: CALGB...  
  Shulman LN, Berry DA, Cirrincione CT, Becker HP, Perez EA, O'Regan R, Martino S, Shapiro CL, Schneider CJ, Kimmick G, Burstein HJ, Norton L, Muss H, Hudis CA, Winer EP, J Clinc Oncology, 1/1/2014
• Genome sequencing of multiple primary tumors reveals a novel PALB2 variant  
  Schrader KA, Stratton KL, Murali R, Laitman Y, Cavallone L, Offit L, Wen YH, Thomas T, Shah S, Rau-Murthy R, Manschreck C, Sal0Mullen E, Otegbeye E, Corines M, Zhang L..., J Clinc Oncology, 1/1/2014
• Breast cancer version 32014  
  Gradishar WJ, Anderson Bo, Blair SL, Burstien JH, Cyr A, Elias AD, Farrar WB, Forero A, Giordano SH, Goldstein LJ, Hayes DF, Hudis CA, Isakoff SJ, Ljung BM, Marcom PK,..., J Natl Compr Netw, 1/1/2014
• Comorbidity, chemotherapy toxicity and outcomes among older women receiving adjuvant chemotherapy for breast cancer on a clinical trial: CALGB 49907 and CALGB 361104 (...  
  Klepin HD, Pitcher BN, Balmman KIV, Kornblith AB, Hurria A, Winer EP, Hudis C, Cohen HJ, Muss HB, Kimmick GG, J Oncol Pract, 1/1/2014
• Sequester cuts may delay drug approvals - and more  
  Hudis CA, Sci Trans Med, 1/1/2014
• Obesity and inflammation: new insights into breast cancer development and progression  
  Iyengar NM, Hudis CA, Dannenberg AJ, Am Soc Clin Oncol Educ Book, 1/1/2013
• Personalizing the treatment of women with early breast cancer; highlights of the St Gallen International  
  Goldhirsch A, Winer EP, Coates AS, Gelber RD, Piccart-Gebhart M, Thurlimann B, Senn HJ, Panel members, Ann Oncol, 1/1/2013
• A phase 1 study evaluating the combination of an allosteric AKT inhibitor (MK-2206) and trastuzumab in patients with HER2-positive solid tumors  
  Hudis C, Swanton C, Janjigian YY, Lee R, Sutherland S, Lehman R, Chandarlapaty S, Hamilton N, Gajria D, Knowles J, Shah J, Shannon K, Tetteh E, Sullivan DM, Moreno S, ..., Breast Cancer Res, 1/1/2013
• A multicenter trial evaluating retaspimycin HCL (IPI-504) plus trastuzumab in patients with advanced metastatic HER2-positive breast cancer  
  Modi S, Saura C, Henderson C, Lin NJ, Lin NU, Mahtani R, Goddard J, Rodena E, Hudis C, O'Shaughnessy J, Baselga J, Breast Cancer Res Treat, 1/1/2013
• Cognitive function in older women with breast cancer treated with standard chemotherapy and capecitabine on Cancer and Leukemia Group B 49907  
  Freedman RA, Pticher B, Keathing NL, Ballman KV, Mandelblatt J, Kornblith AB, Kimmick GG, Hurria A, Winer EP, Hudis CA, Cohen HJ, Muss HB for Alliance for Clinical Tri..., Breast Cancer Res Treat, 1/1/2013
• Risk of metaschronous breast cancer after BRCA mutation-associated ovarian cancer  
  Domchek SM, Jhaveri K, Patil S, Stopfer JE, Hudis C, Powers J, Stadler Z, Goldstein L, Kauff N, Khasraw M, Offit K, Nathanson KL, Robson M, Cancer, 1/1/2013
• Risk of metachronous breast cancer after BRCA mutation0 associated ovarian cancer  
  Domeck SM, Jhaveri K, Patil S, Stopfer JE, Hudis C, Powers J, Stadler Z, Goldstein L, Kauff N, Khasraw M, Offit K, Nathanson KL, Robson M, Cancer, 1/1/2013
• Magnetic resonance imaging as a predictor of pathologic response in patients treated with neoadjuvant systemic treatment for operable breast cancer  
  De Los Santos JF, Cantor A, Amos KD, Forero A, Golshan M, Horton JK, Hudis CA, Hylton NM, McGuire K, Maric-Bernstam F, Meszoely IM, Nanda R, Hwang ES, Cancer, 1/1/2013
• Prognostic value of quantitative fluorodeoxyglucose measurements in newly diagnosed metastatic breast cancer  
  Ulaner GA, Eaton A, Morris PG, Lilienstein J, Jhaveri K, Patil S, Fazio M, Larson S, Hudis CA, Jochelson MS, Cancer Medicine, 1/1/2013
• Caloric restriction reverses obesity induced mammary gland inflammation in mice  
  Bhardwaj P, Baoheng Du, Xi KZ, Sue E, Harbus MD, Falcone DJ, Giri D, Hudis CA, Kopelovich, L, Cancer Prev Res, 1/1/2013
• Increased levels of urinary PGE-M, a biomarker of inflammation, occur in association with obesity, aging, and lung metastases in patients with breast cancer  
  Morris PG, Zhou XK, Milne GL, Goldstein D, Hawks LC, Dang CT, Modi S, Fornier MF, Hudis CA, Dannenberg AJ, Cancer Prev Res, 1/1/2013
• Dietary polyphenols suppress elevated levels of proinflammatory mediators and aromatase in the mammary gland of obese mice  
  Subbaramaiah K, Sue E, Bhardwaj P, Du B, Hudis CA, Giri D, Kopelovich L, Zhou XK, Dannenberg A, Cancer Prev Res, 1/1/2013
• Join now to see all

Books/Book Chapters

• Diseases of the Breast 
  Chapter: Implications of breast cancer. 
  Page 700 - 708Gucalp A, Morris PG, Hudis CA, Dannenberg AJEditors: Harris JR, Lippman ME, Morrow, M Osborne CK.Lippincott, Williams & Wilkins, Philadelphia, PAEdition 5th,2014
• Diseases of the Breast 
  Chapter: Adjuvant systemic chemotherapy in early breast cancer. 
  Page 635 - 648Hudis CA, Dang CEditors: Harris JR, Lippman ME, Morrow, M Osborne CK.Lippincott, Williams & Wilkins, Philadelphia, PAEdition 5th,2014
• Future of Medicine 
  Chapter: Advances in Management of Triple Negative. 
  Hudis C, Traina TAEditors: Tiffany Traina.Future Medicine Ltd, London, United Kingdom2011
• Emerging Cancer Therapeutics 
  Chapter: Adjuvant chemotherapy for breast cancer: updates and new perspectives. 
  Page 495 - 507Murphy C, Hudis CA, McArthur HLEditors: Tan AR.Demos Medical Publishing, New York, NY2011
• New treatment paradigms in metastatic breast cancer 
  Dang C and Hudis C (Eds)Editors: Dang C and Hudis C.CMPMedica, London, England2008
• Breast Cancer 
  Winchester DJ, Winchester DP, Hudis C, Norton L (Eds)Editors: Winchester DJ, Winchester DP, Hudis C, Norton L.BC Decker, Hamilton, Ontario, CanadaEdition 2nd,2006
• Principles and Practice of Gynecologic 
  Chapter: Breast Cancer. 
  Page 1077 - 1170McCormick B, Hudis C, Gemignani M, Dershaw DD, Tan LK, Perez CA, Taylor MEEditors: Hoskins WJ, Perez CA, Young RC, Barakat R, Markman M, Randall M.Lippincott Williams & Wilkins, Philadelphia, PAEdition 4th,2005
• Breast Cancer 
  Chapter: Systemic Treatment for Stage I and Stage II Breast Cancer. 
  Page 537 - 556Hudis C and Norton LEditors: Roses DF.Elsevier, Philadelphia, PA2005
• Principles and Practice of Gynecologic Oncology 
  Chapter: Breast Cancer. 
  Page 1077 - 1170McCormick B, Hudis C, Gemignani M, Dershaw DD, Tan LK, Perez CA, Taylor MEEditors: Hoskins WJ, Perez CA, Young RC, Barakat R, Markman M, Randall M.Lippincott Williams & Wilkins, Philadelphia, PAEdition 4th,2005
• Progress in Oncology 
  Chapter: The concept of dose density and its application to the adjuvant chemotherapy of node-positive primary breast cancer. 
  Page 290 - 318Norton L, Hudis CEditors: Devita VT Jr, Hellman S, Rosenberg SA.Jones and Bartlett Publishers, Sudbury, MA2005
• Diseases of the Breast 
  Chapter: Rare Cancers in the Breast. 
  Page 1015 - 1033Hudis C, Tan LKEditors: Harris JR, Lippman ME, Morrow M, Osborne CK.Lippincott, Williams & Wilkins, Philadelphia, PAEdition 3rd,2004
• Textbook of Breast Cancer: A Clinical Guide to Therapy 
  Chapter: Conventional Adjuvant Chemotherapy. 
  Page 139 - 149Hudis CEditors: Bonadonna G, Hortobagyi GN, Gianni AM.Martin Dunitz Ltd, London, United KingdomEdition 2nd,2000
• Principle and Practice of Gynecologic Oncology 
  Chapter: Breast Cancer. 
  Page 1139 - 1239McCormick B, Hudis C, Heerdt A, Borgen PI, Dershaw DD, Tan LK, Perez CA, Taylor MEEditors: Hoskins WJ, Perez CA, Young RC.Lippincott Williams & Wilkins, Philadelphia, PAEdition 3rd,2000
• ASCO Educational Book 
  Chapter: Chemotherapy for Early-stage Breast Cancer. 
  Page 266 - 273Hudis CEditors: Perry MC.American Society of Clinical Oncology, Alexandria, VA2000
• Progress in Anti-Cancer Chemotherapy. Volume IV 
  Chapter: How Should We Integrate New Drugs in the Treatment of Metastatic Breast Cancer? 
  Page 225 - 231Hudis CEditors: Khayat D, Hortobagyi GN.Blackwell-Science, Malden, MA2000
• Breast Cancer 
  Chapter: Systemic Treatment of Stage I and Stage II Breast Cancer. 
  Page 417 - 444Hudis C, Norton LEditors: Roses DF.Churchill Livingstone, Philadelphia, PA1999
• Should this Woman Receive Postmastectomy Adjuvant Therapy? 
  Hudis C1994
• Adjuvant Therapy of Cancer VII 
  Chapter: Dose-Intensive Sequential Crossover Adjuvant Chemotherapy for Women with High Risk Node-Positive Breast Cancer. 
  Page 214 - 219Hudis C, Lebwohl D, Crown J, Gilewski T, Surbone A, Hakes T, Currie V, Seidman A, Reichman B, Harrison M, Bellittieri R, Hamilton N, Norton LEditors: Salmon SE.JB Lippincott Company, Philadelphia, PA1993
• Mediguide to Oncology 
  Chapter: Metastatic Breast Cancer 
  Hudis C, Norton LEditors: Weirnik PH.1993
• Current topics in surgical oncology 
  Chapter: Current status of Adjuvant Chemotherapy in the Treatment of Colorectal Cancer. 
  Page 485 - 502Hudis C, Kelsen DEditors: Fegiz, G, Ramacciato, G, Vitelli, C, De Angelis, R.Masson S.P.A., Milan, Italy1991
• Join now to see all

Lectures

• Continuing Medical Education (CME) Comprehensive Oncology Review 
  Continuing Medical Education Institute, Inc, Seattle, Washington - 9/22/2012

Other

• Dose-dense chemotherapy: ready for prime time. 
  Dang CT and Hudis CA, Breast Cancer Online
  http://www.bco.org/my_bco.asp
  1/1/2005
• Letrozole after tamoxifen improves disease-free survival from women with breast cancer (expert comments). 
  Hudis C
  www.breastcancercare.org